MONTREAL, March 17, 2005 (PRIMEZONE) -- Viropro Pharma, a subsidiary of Viropro, Inc. (OTCBB:VPRO) is pleased to announce the addition of Dr. Jean-Marie Dupuy to its scientific advisory committee.
Dr. Dupuy is a renowned expert in biotechnology with major contributions in the areas of project development, research and clinical implementation for several pharmaceutical and biotech companies.
Dr. Dupuy was previously Vice-President, Medical & Regulatory Affairs at Immuno-designed Molecules Company; Project Director, Immunology / Oncology Programs at Wyeth Ayerst; and Medical Director at Pasteur Merieux Connaught. In addition, he was author and co-author of more than 240 scientific and medical articles, books and publications.
Prior to joining the Pharmaceutical Industry, Dr. Dupuy held several academic positions in Canada and France. In Canada, he was Director of Clinical Immunology, Montreal Children's Hospital and Director of the Immunology Research Center, Armand Frappier Institute, Montreal. In France, he held the post of Deputy Director of the Department of Paediatric Liver Diseases, Bicetre Children's Hospital, Paris and head of The Immunology and Virology Research Centre. Dr Dupuy has conducted intensive clinical & research activities in Paediatrics, Immunology, Virology and Vaccines. He received his post-doctoral training in Minneapolis.
Mr. Richard Lee, President of Viropro, Inc. remarked that, "We are very pleased to welcome Dr. Dupuy to our committee of five prestigious biotechnology experts and internationally-recognized doctors. His previous involvement in several high profile biotech projects will definitely enhance Viropro Pharma's team." Dr. Dupuy responded, "I am very pleased to be part of this committee of recognized doctors and scientists and look forward to contributing to the development of Viropro Pharma's business portfolio and its dynamic influence on international markets."
About Viropro, Inc.
Viropro, Inc. (OTCBB:VPRO) is establishing a growth portfolio in Life Sciences markets through strategic alliances and revenue-producing acquisitions with the potential for continued shareholder value.
Viropro, Inc.'s Safe Harbor Statement
Except for any historic information contained herein, the matters discussed in this press release contain forward-looking statements that involve risks and uncertainties, which are subject to section 27A of the Securities Act of 1933 and section 21E of the Exchange Act of 1934, and are subject to safe harbor created by these sections. Any statements that express or involve discussions with respect to predictions, beliefs, plans, projections, objectives, goals, assumptions of future events or performances are not statements of historical fact and may be "forward looking statements". Forward looking statements in this release may be identified through the use of such words as "expects", "anticipates", "estimates", "believes", or statements indicating certain actions "may", "could", or "might" occur. Actual results, performance or achievements could differ materially from those anticipated in such forward-looking statements, which involve numerous risks and uncertainties, including the Company's ability to market its products and services in a competitive environment as well as other factors.
Direct all inquiries to Trivor Financial Communications.